Home » Stocks » STXS

Stereotaxis, Inc. (STXS)

Stock Price: $6.70 USD 0.29 (4.52%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 496.34M
Revenue (ttm) 26.63M
Net Income (ttm) -8.02M
Shares Out 72.75M
EPS (ttm) -0.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $6.70
Previous Close $6.41
Change ($) 0.29
Change (%) 4.52%
Day's Open 6.42
Day's Range 6.42 - 6.72
Day's Volume 255,422
52-Week Range 3.03 - 8.62

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ST. LOUIS, April 19, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will releas...

2 weeks ago - GlobeNewsWire

ST. LOUIS, April 12, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that David Fischel, Chair...

3 weeks ago - GlobeNewsWire

ST. LOUIS, April 07, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that Broward Health Medic...

1 month ago - GlobeNewsWire

Robotics stocks should have years of growth ahead as the trend toward automation continues. These 5 names aren't cheap, but look worth paying up for.

Other stocks mentioned: ABB, IRBT, ISRG, RAAC
1 month ago - InvestorPlace

Stereotaxis Inc. (STXS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down ...

2 months ago - Zacks Investment Research

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of 0.00% and 15.68%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

ST. LOUIS, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for...

2 months ago - GlobeNewsWire

ST. LOUIS, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a 10-year CEO perfor...

2 months ago - GlobeNewsWire

ST. LOUIS, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, ...

2 months ago - GlobeNewsWire

ST. LOUIS, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release...

3 months ago - GlobeNewsWire

Stereotaxis, Inc. (STXS) CEO David Fischel on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Stereotaxis, Inc.'s (STXS) CEO David Fischel on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

ST. LOUIS, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for...

6 months ago - GlobeNewsWire

ST. LOUIS, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release...

6 months ago - GlobeNewsWire

ST. LOUIS, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced it has complete...

7 months ago - GlobeNewsWire

ST. LOUIS, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fisc...

8 months ago - GlobeNewsWire

ST. LOUIS, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fisch...

8 months ago - GlobeNewsWire

ST. LOUIS, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a pioneering pub...

8 months ago - GlobeNewsWire

Stereotaxis, Inc. (STXS) CEO David Fischel on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

ST. LOUIS, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results...

9 months ago - GlobeNewsWire

ST. LOUIS and CARLSBAD, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Acutus Medical today announced the first integrated cardiac ablation procedure benefiting from remote...

9 months ago - GlobeNewsWire

ST. LOUIS, July 23, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will rel...

9 months ago - GlobeNewsWire

ST. LOUIS, July 13, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publication in...

9 months ago - GlobeNewsWire

ST. LOUIS, June 22, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that the company...

10 months ago - GlobeNewsWire

Robotics stocks offer multi-decade growth potential. These 10 stocks offer some of the best exposure to this attractive trend.

Other stocks mentioned: ABB, AVAV, BOTZ, FLIR, GMED, IRBT, ISRG ...
10 months ago - InvestorPlace

ST. LOUIS, June 18, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fisch...

10 months ago - GlobeNewsWire

ST. LOUIS, June 02, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced it has reached a...

11 months ago - GlobeNewsWire

ST. LOUIS, May 26, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has entered...

11 months ago - GlobeNewsWire

Stereotaxis, Inc. (STXS) CEO David Fischel on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Stereotaxis, Inc. (STXS) CEO David Fischel on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

ST. LOUIS, March 06, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today it has received U...

1 year ago - GlobeNewsWire

Stereotaxis: A Small But Stellar Performer In The Medical Robotics Space

1 year ago - Seeking Alpha

Stereotaxis: Poised For A Strong 2020

1 year ago - Seeking Alpha

ST. LOUIS, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that HCA Midwest...

1 year ago - GlobeNewsWire

A series of financial missteps led to a delisting for Stereotaxis in 2013. Now that a new CEO has made some progress toward a turnaround, the robotic technology company may deserve a second chance.

1 year ago - The Motley Fool

Stereotaxis, Inc. (STXS) CEO David Fischel on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

ST. LOUIS and MT. OLIVE, N.J., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE American: STXS) and Catheter Precision today announced the first patients have been successfully treated with the...

1 year ago - GlobeNewsWire

ST. LOUIS and PESSAC, France, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE American: STXS) and inHEART today announced the first patients have been successfully treated with the integration...

1 year ago - GlobeNewsWire

ST. LOUIS and BARCELONA, Spain, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE American: STXS) and ADAS 3D Medical SL today announced the first patients have been successfully treated with th...

1 year ago - GlobeNewsWire

Accuray and Stereotaxis are hyper-focused on growth.

Other stocks mentioned: ARAY, ISRG, MDT, SYK, VAR
1 year ago - The Motley Fool

ST. LOUIS, Mo., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE American: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced t...

1 year ago - GlobeNewsWire

About STXS

Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Ody... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Aug 12, 2004
CEO
David Fischel
Employees
120
Stock Exchange
NYSEAMERICAN
Ticker Symbol
STXS
Full Company Profile

Financial Performance

In 2020, Stereotaxis's revenue was $26.63 million, a decrease of -7.86% compared to the previous year's $28.90 million. Losses were -$6.65 million, 44.8% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Stereotaxis stock is "Strong Buy." The 12-month stock price forecast is 9.33, which is an increase of 39.25% from the latest price.

Price Target
$9.33
(39.25% upside)
Analyst Consensus: Strong Buy